Equities

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Actions
  • Price (EUR)7.33
  • Today's Change-0.03 / -0.41%
  • Shares traded0.00
  • 1 Year change+55.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments389424508
Total Receivables, Net575129
Total Inventory292816
Prepaid expenses20139.99
Other current assets, total1.801.473.35
Total current assets496517566
Property, plant & equipment, net211515
Goodwill, net------
Intangibles, net------
Long term investments0186.83
Note receivable - long term------
Other long term assets0.08----
Total assets517550588
LIABILITIES
Accounts payable211428
Accrued expenses1049074
Notes payable/short-term debt000
Current portion long-term debt/capital leases25----
Other current liabilities, total01.221.42
Total current liabilities150106104
Total long term debt814733585
Total debt839733585
Deferred income tax------
Minority interest------
Other liabilities, total8.395.805.96
Total liabilities972845695
SHAREHOLDERS EQUITY
Common stock2.061.881.84
Additional paid-in capital1,2221,1581,098
Retained earnings (accumulated deficit)(1681)(1455)(1208)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.340.030.18
Total equity(456)(295)(107)
Total liabilities & shareholders' equity517550588
Total common shares outstanding206188184
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.